NNIT has been recognized by APAC CIOOutlook Magazine as the recipient of “Top Life Science Technology Consulting Companies in APAC,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the APAC CIOOutlook research and editorial team based on insights from an interview with Jason Zhen Sheng Xing.

NNIT
Delivering Agility to the Life Sciences Industry

Jason Zhen Sheng Xing, General Manager, NNIT China

Digitalization of drug development processes in the life sciences industry has paved the way for improved efficiency, streamlined compliance, and engaging customer experiences. However, mere successful execution of a digital strategy alone does not necessarily guarantee quality and rapid production of pharmaceutical products for these organizations. Analyzing the requirements of life sciences industry and implementing relevant digital technologies is paramount for accelerating drug development while maintaining data security and traceability of a medicine’s origin. To help organizations in the deployment of cutting-edge technologies effectively, NNIT an international IT service provider, delivers IT consultancy services and assists pharmaceutical organizations in increasing their capabilities pertaining to value chain, quality management, serialization, and more.

NNIT amalgamates IT with life sciences to drive the digital transformation of drug manufacturing, business operations, and consultation. By comprehending multiple business needs, NNIT improves clinical trial productivity, increases research and development (R&D) throughput, and accelerates drug production. It also enables the integration of in-house native databases with each other, migration of data from legacy infrastructure to cloud, and optimization of the workflow to decrease a product’s time-to-market interval while maintaining compliance with GxP and other regulations. “With our profound experience and domain expertise, we add value to our clients’ business by making them agile in their day-to-day operations,” adds Jason Zhen Sheng Xing, general manager of NNIT China.

The organization further helps life sciences firms during audits through paperless validation, resulting in operational cost savings and faster inspections.

The key differentiating factor of NNIT is its ability to build flexible platforms that align with the evolving drug development prerequisites. In tandem with this, the company uses its proprietary Advising, Building, Operating and Supporting (ABOS) service model to understand clients’ businesses at the commencement of collaborations. Following this, it builds a customized platform for clients and then maintains it for the next five to ten years. During that period, NNIT continues to enhance the platform’s functionalities to provide its clientele a competitive advantage. “The ABOS model offers a comprehensive solution set, thereby improving productivity and efficiency in the manufacturing of drugs,” states Xing.

NNIT understands the importance of quality in the life sciences industry as the output of drug discovery impacts patient safety. Therefore, the company offers a wide range of quality management services such as test, validation, and compliance to optimize outputs, ensuring that its clients’ IT systems are aligned with various regulatory requirements of life sciences sector.

Over the years, quality management has been at the center of NNIT’s competencies; therefore it has garnered a vast clientele, comprising some of the largest pharmaceutical institutions. An illustration of its proficiency in catering to client requirements can be exemplified through a success story that sheds light on its approach to delivering IT solutions. NNIT assisted a client in developing a sophisticated pharmaceutical supply chain platform that caters to several business functions such as online drug orders and drug distribution channel management. Consequently, the client obtained an overview of their business operations and could manage sales activities effectively.

Such outcomes have catalyzed NNIT to further partner with various organizations that are pioneering in virtual reality (VR) to enhance its services and help the most heavily regulated life sciences industry. It is also exploring the potential of artificial intelligence (AI) and robotic process automation (RPA) to minimize the risk of errors in the development of drugs and open new doors to newer business opportunities. “We are committed to collaborating with pharmaceutical organizations by inculcating cutting-edge technologies that include big data, internet of things (IoT), and more into our solutions portfolio to ensure scalability and flexibility in their business operations,” concludes Xing.

NNIT News

NNIT A/S: NNIT acquires fast-growing US company to accelerate delivery of IT services to the international life sciences industry

Copenhagen- NNIT A/S announces that it has acquired Valiance Partners, LLC (Valiance Partners). The acquisition will lift NNIT's growth and strengthen its position as a leading IT services provider for the global life sciences industry.

Valiance Partners, headquartered in New Jersey close to NNIT's US office, is recognized and referenced as one of the strongest providers of migration services for the rapidly growing Software-as-a-Service (SaaS) platforms to primarily pharmaceutical companies.

Over the past three years, Valiance Partners has grown by more than 40% annually, working with many of the largest pharma companies in North America, Europe and Japan.

The two companies have already collaborated on several projects and complement each other very well, explains Per Kogut, CEO, NNIT:

"Valiance Partners provides a perfect strategic and cultural match and I am excited to welcome this fast-growing company to NNIT. They come with a strong experience and have delivered migration services to many of the world's most successful pharmaceutical companies. Together we will strengthen our growth potential and the acquisition will boost NNIT as a global IT provider to the international life sciences industry."

The demand for migration services has increased significantly during the past couple of years, as more and more life sciences companies implement cloud-based platforms to collect and integrate data and transform business processes.

"We are excited to become part of the NNIT Group and continue our successful growth," says Richard Higger, co-founder and CEO, Valiance Partners. "With NNIT's experience in international life sciences, we see an opportunity to expand our successful business in additional markets. Our two companies have already collaborated on several projects and learned that we make a good fit."

Valiance Partners - ranked among the fastest-growing companies in the US - has managed and successfully completed more than 500 migrations for over 100 clients, including many of the world's leading pharmaceutical, medical device and biotechnology companies.

One of the key platforms supported by Valiance Partners' proprietary software is Veeva Vault, a unified suite of applications for clinical, regulatory and quality, which enables companies to drive greater efficiency and maintain compliance throughout the product lifecycle.

Valiance Partners, LLC is currently employing 60+ people in its offices in New Jersey, US, and Dublin, Ireland. In order to focus on its current strong growth, Valiance Partners, LLC will continue to operate as an independent company under the name "Valiance Partners - an NNIT Group Company."